Deals this week: bluebird bio, arGEN-X BV, Hookipa Biotech

15th December 2017 (Last Updated December 15th, 2017 00:00)

US-based clinical-stage biotechnology firm bluebird bio Inc has raised $600m through a public offering of 3,243,244 shares of its common stock priced at $185 a share.

US-based clinical-stage biotechnology firm bluebird bio Inc has raised $600m through a public offering of 3,243,244 shares of its common stock priced at $185 a share.

Underwriters will be granted a 30-day option to buy additional 486,486 shares of common stock.

The firm will use funds to advance the development of its bb2121 product candidate, fund phase one clinical study of a bb21217 product candidate, and for other general corporate purposes.

arGEN-X BV plans to raise €127.46m ($150m) through a public offering of American depositary shares (ADS) priced at €0.10 ($0.12) a unit.

The Netherlands-based clinical-stage biotechnology company plans to use funds to advance development of its drug candidates ARGX-113 and ARGX-110 and for other general corporate purposes.

Austrian clinical-stage biotech firm Hookipa Biotech AG has secured €50m ($58.84m) in a series C funding round.

The company will use the funds to perform phase two study of prophylactic Cytomegalovirus (CMV) vaccine in patients who have undergone organ transplants, and extend its technology platform for treatment of prostate cancer.

"Cancer Genetics Inc intends to raise $7m through the private placement of 3.5 million units priced at $2 each."

NorthSea Therapeutics BV (NST) has secured €25m ($29.46m) in a series A venture funding round.

Based in the Netherlands, NST is a clinical-stage biotech company that develops fatty acid therapeutics.

The company intends to use funds to develop a structurally engineered fatty acid (SEFA) called icosabutate and to carry out clinical and non-clinical toxicology studies.

Synlogic Inc has partnered with biotechnology company Ginkgo BioWorks Inc to develop medicines for neurological and liver disorders.

Synlogic is a developer of probiotic bacteria for treatment of metabolic and inflammatory diseases.

Both companies involved in the transaction are based in the US.

Cancer Genetics Inc intends to raise $7m through the private placement of 3.5 million units priced at $2 each.

Each unit includes one share of common stock and a warrant.

Cancer Genetics is a provider of precision medicine for oncology, and intends to use the proceeds for general corporate purposes.